Open Science Research Excellence

Congo Tak Shing Ching

Publications

1

Publications

1
8651
An Immunosensor for Bladder Cancer Screening
Abstract:
Nuclear matrix protein 22 (NMP22) is a FDA approved biomarker for bladder cancer. The objective of this study is to develop a simple NMP22 immumosensor (NMP22-IMS) for accurate measurement of NMP22. The NMP22-IMS was constructed with NMP22 antibody immobilized on screen-printed carbon electrodes. The construction procedures and antibody immobilization are simple. Results showed that the NMP22-IMS has an excellent (r2³0.95) response range (20 – 100 ng/mL). In conclusion, a simple and reliable NMP22-IMS was developed, capable of precisely determining urine NMP22 level.
Keywords:
Bladder Cancer, Immunosensor, Impedance, NMP22